Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
Guardado en:
Autores principales: | Philippine Eloy, Roger Le Grand, Denis Malvy, Jérémie Guedj |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/68c05c7308194316980c882e8a2f82de |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
por: Jean-Sélim Driouich, et al.
Publicado: (2021) -
Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
por: Ching-Chi Lee, et al.
Publicado: (2021) -
Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?
por: Lei Zhao, et al.
Publicado: (2021) -
A novel model of molnupiravir against SARS-CoV-2 replication: accumulated RNA mutations to induce error catastrophe
por: Yuxi Zhao, et al.
Publicado: (2021) -
Molnupiravir; an effective drug in treating COVID-19?
por: Alireza Pouramini, et al.
Publicado: (2022)